Screening women at high risk of breast cancer on the basis of evidence

European Journal of Radiology

Volumn 39, Issue 1, 2001, Pages 50-59

  Warren, Ruth ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

BRCA gene mutation; Breast cancer; Family history; Mammography; Radiation risk; Screening

Indexed keywords

GENETIC ENGINEERING; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; RADIATION; SCREENING; SURGERY; TUMORS; ULTRASONICS;

BREAST CANCER;

RADIOLOGY;

BRCA1 PROTEIN; BRCA2 PROTEIN; FLUORODEOXYGLUCOSE F 18;

ADULT; BREAST CANCER; CANCER SCREENING; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; IMAGING; MAMMOGRAPHY; MASS SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; REVIEW; RISK ASSESSMENT; ULTRASOUND;

ADULT; BREAST NEOPLASMS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034952399     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(00)00237-0     Document Type: Review

References (133)

1. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization
2. An overview of the Swedish randomised mammography trials: total mortality pattern and the representivity of the study cohorts
3. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan
4. 14 Years of follow-up from the Edinburgh randomised trial of breast-cancer screening
5. Recent results from the Swedish Two-County Trial: the effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening
6. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer
7. Mammography screening: an incremental cost effectiveness analysis of double versus single reading of mammograms
8. Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London
9. Trial design based on surrogate end points - application to comparison of different breast screening frequencies
10. Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging
11. Circulating tumor markers in breast cancer: accepted utilities and novel prospects
12. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
13. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms
14. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
15. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
16. Inherited breast and ovarian cancer
17. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer
18. Inherited breast and ovarian cancer. What are the risks? What are the choices?
19. Consortium CGS. Recommendations for follow-up care of individuals with an inherited predisposition to cancer ii. BRCA1 and BRCA2
20. The endocrine prevention of breast cancer
21. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
22. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
23. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
24. Complications leading to surgery after breast implantation
25. Ovarian cancer family and prophylactic choices
26. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
27. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
28. The natural history of breast carcinoma
29. Assessment of radiation risk from screening mammography
30. Cancers detected and induced in mammography screening: new screening schedules and younger women with family history
31. Benefits versus risks from mammography. A critical assessment
32. Pain coping and the pain experience during mammography: a preliminary study
33. Imaging of the radiographically dense breast
34. Occult cancer in women with dense breasts: detection with screening US - diagnostic yield and tumor characteristics
35. Malignant breast masses detected only by ultrasound. A retrospective review
36. Experience enhances mammographic interpretation, doesn't it? Yes, it does!
37. Computer-aided diagnosis in full digital mammography
38. Just how valuable is double reporting in screening mammography?
39. Effect of age, breast density, and family history on the sensitivity of first screening mammography
40. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme
41. Estimating mean glandular dose using proprietary mammography phantoms
42. Dose and image quality in mammography with an automatic beam quality system
43. Effect of automatic kV selection on dose and contrast for a mammographic X-ray system
44. A pilot survey of radiation doses received in the United Kingdom Breast Screening Programme
45. Breast cancer induction due to mammographic screening in hereditarily affected women
46. Genetic susceptibility to cancer
47. Incidence of female breast cancer among atomic bomb survivors, 1950-1985
48. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer
49. A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose
50. Early-onset breast cancer in A-bomb survivors
51. Breast cancer after multiple chest fluoroscopies: second follow-up of Massachusetts women with tuberculosis
52. The risk of breast cancer after irradiation of the thymus in infancy
53. Adjuvant radiotherapy and risk of contralateral breast cancer
54. Critical target and dose and dose-rate responses for the induction of chromosomal instability by ionizing radiation
55. Effect of radiation quality on lesion complexity in cellular DNA
56. The repair of ionising radiation-induced damage to DNA
57. Radiation mutagenesis: the initial DNA lesions responsible
58. Radiosensitivity in ataxia telangiectasia
59. Role of the ataxia-telangiectasia gene (ATM) in breast cancer
60. 'At risk' for breast cancer
61. Cancer risks in A-T heterozygotes
62. Breast cancer and radiotherapy in ataxia-telangiectais heterozygote
63. A critical look at the association of human genetic syndromes with sensitivity to ionizing radiation
64. Heterozygous ATM mutations do not contribute to early onset of breast cancer
65. Exclusion from mammographic screening of women genetically predisposed to breast cancer will probably eliminate mammographically induced breast cancer
66. p53 And the Li-Fraumeni syndrome
67. The Breast Cancer Screening Controversy and the National Institutes of Health Consensus development Conference on Breast Cancer screening for Women aged 40-49
68. Lessons from the mammography screening controversy: can we improve the debate?
69. Benefits and risks of screening mammography for women in their forties: a statistical appraisal
70. False positive findings of mammography will have psychological consequences
71. American and European recommendations for screening mammography in younger women: a cultural divide?
72. Breast cancer screening for younger women is not an efficient use of resources
73. Value of mammography for women aged 40-49
74. Breast cancer screening in women aged under 50 - Slower and smaller benefits, and more frequent adverse effects
75. Clinical value of mammography for symptomatic women 35 years of age and younger
76. Screening mammography: value in women 35-39 years old
77. Is mammography useful in the detection of breast cancer in women 35 years of age or younger?
78. Mammographic detection of breast cancer in women under the age of 35
79. Short communication: breast parenchymal patterns and their changes with age
80. Breast carcinomas occurring in young women (35 years) are different
81. Are breast cancers in young women qualitatively distinct?
82. Studying mammographic density: implications for understanding breast cancer
83. Mammographic features and breast cancer risk: effects with time, age, and menopause status
84. The effect of hormone replacement therapy on the sensitivity of screening mammograms
85. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme
86. What is the role of sonographic breast imaging for detecting occult cancer in a patient with a strong family history of breast cancer and mammographically dense breasts without obvious masses?
87. Sonography of the breast
88. MRI of the breast: state of the art
89. Breast magnetic resonance imaging
90. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions
91. Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme
92. Genetic analysis of mammographic breast density in adult women: evidence of a gene effect
93. Mammographic densities and risk of breast cancer among subjects with a family history of this disease
94. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
95. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density
96. Can mammographic densities predict effects of tamoxifen on the breast?
97. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen
98. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee
99. Effect of hormone replacement therapy on cancer detection by mammography
100. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases
101. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
102. Screening women aged less than 50 years with a family history of breast cancer
103. Screening for breast and ovarian cancer: the relevance of family history
104. Screening by mammography, women with a family history of breast cancer
105. Ultrasound breast examination of asymptomatic patients with normal but radiodense mammograms
106. The current role of ultrasonography in breast imaging
107. Solid breast lesions: diagnosis with US-guided fine-needle aspiration biopsy
108. MRI in breast cancer diagnosis and treatment
109. MRI efficacy and effectiveness research: who needs it and who pays for it?
110. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging
111. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model
112. MR-guided percutaneous excisional and incisional biopsy (PEIB) of breast lesions
113. Interventional MRI of the breast:leson localisation and biopsy
114. Interventional breast MR imaging: clinical use of a stereotactic localization and biopsy device
115. Healthy premenopausal breast parenchyma in dynamic contrast -enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency
116. Observer variability in the interpretation of contrast enhanced MRI of the breast
117. National study of magnetic-resonance imaging to screen women at genetic risk of breast cancer
118. The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis
119. Scintigraphic imaging of breast cancer: a review
120. PET in breast cancer
121. Sensitivity and specificity of planar scintimammography with 99mTc-sestamibi
122. Scintimammographic analysis of nonpalpable breast lesions previously identified by conventional mammography
123. Overview of the current status of PET in breast cancer imaging
124. Investigation and management of patients at high risk of developing cancer
125. Psychosocial and ethical implications of defining genetic risk for cancers
126. Mammography and malpractice litigation: current status, lessons, and admonitions
127. Medicolegal aspects of breast imaging, Radiol
128. Future challenges in secondary prevention of breast cancer for women at high risk
129. Report of the International Workshop on Screening for Breast Cancer